Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Drugs industry as a whole closed the day up 0.6% versus the S&P 500, which was up 0.1%. Laggards within the Drugs industry included CymaBay Therapeutics ( CYMA), down 2.2%, Aoxing Pharmaceutical ( AXN), down 7.0%, Vermillion ( VRML), down 2.7%, Cellectar Biosciences ( CLRB), down 6.1% and Sophiris Bio ( SPHS), down 1.7%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today: Cellectar Biosciences ( CLRB) is one of the companies that pushed the Drugs industry lower today. Cellectar Biosciences was down $0.16 (6.1%) to $2.48 on average volume. Throughout the day, 18,700 shares of Cellectar Biosciences exchanged hands as compared to its average daily volume of 20,000 shares. The stock ranged in price between $2.40-$2.66 after having opened the day at $2.66 as compared to the previous trading day's close of $2.64. Cellectar Biosciences has a market cap of $20.4 million and is part of the health care sector. Shares are unchanged year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Cellectar Biosciences a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.